Burning Rock Biotech (BNR) Debt to Equity (2019 - 2025)

Burning Rock Biotech (BNR) posted quarterly Debt to Equity of $0.0 for Q1 2026, up 3.21% on a QoQ basis from $0.0 in Q4 2025.

Burning Rock Biotech (BNR) Debt to Equity (2019 - 2025) Analysis & Trends

Burning Rock Biotech (BNR) has reported Debt to Equity for 5 consecutive years, with $0.0 the latest figure, recorded in Q1 2026.

In Q1 2026, Debt to Equity changed N/A year-over-year to $0.0; the TTM figure through Mar 2026 stood at $0.0 (changed N/A YoY), while the FY2025 annual figure was $0.0, changed N/A from the prior year.
Debt to Equity came in at $0.0 for Q1 2026 at Burning Rock Biotech, up from $0.0 in the prior quarter.
The five-year high for Debt to Equity was $0.0 in Q1 2026, with the low at $0.0 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt/Equity (Qtr)
1	Waters	31,055.11 Bn	31,054.65 Bn	1.11 Bn	0.32
2	Thermo Fisher Scientific	191.02 Bn	187.77 Bn	7.74 Bn	0.83
3	Danaher	137.16 Bn	131.47 Bn	3.59 Bn	0.35
4	Idexx Laboratories	42.82 Bn	42.62 Bn	722.74 Mn	0.53
5	Natera	39.09 Bn	37.99 Bn	696.04 Mn	0.01
6	Agilent Technologies	37.61 Bn	35.81 Bn	990.00 Mn	-1.50
7	Iqvia Holdings	34.23 Bn	32.25 Bn	1.36 Bn	2.49
8	Illumina	28.14 Bn	26.98 Bn	721.00 Mn	0.56
9	Mettler Toledo International	26.40 Bn	26.33 Bn	555.82 Mn	-53.21
10	Burning Rock Biotech	748.66 Mn	683.48 Mn	11.31 Mn	-

Download Data